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SUMMARY
The gastrointestinal tract regulates the trafficking of macromolecules between the environment and the 
host through an epithelial barrier mechanism and is an important part of the immune system controlling the 
equilibrium between tolerance and immunity to non-self-antigens. Various evidence indicates that intestinal 
inflammation occurs in patients with rheumatic diseases. In many rheumatic diseases intestinal inflammation 
appears to be linked to dysbiosis and possibly represents the common denominator in the pathogenesis of 
different rheumatic diseases. The continuative interaction between dysbiosis and the intestinal immune system 
may lead to the aberrant activation of immune cells that can re-circulate from the gut to the sites of extra-
intestinal inflammation as observed in patients with ankylosing spondylitis. The exact contribution of genetic 
factors in the development of intestinal inflammation in rheumatic diseases needs to be clarified.
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n	 INTRODUCTION
The gastrointestinal (GI) tract is an organ system within humans that digests food 
to extract and absorb energy and nutrients, 
expelling the remaining waste as faeces and 
urine. In particular, the GI tract regulates the 
trafficking of macromolecules between the 
environment and the host through an epi-
thelial barrier mechanism (1). The Gl tract 
is an important part of the immune system: 
the intestinal epithelial barrier, together with 
the gut-associated lymphoid tissue and the 
neuroendocrine network, play in fact a fun-
damental role in controlling the equilibrium 
between tolerance and immunity to non-
self-antigens (1). Dysregulation of this or-
gan, in genetically susceptible individuals, 
may lead to both intestinal and extra-intes-
tinal autoimmune disorders (1). The large 
intestine hosts many trillions of microbes, 
the so-called microbiota, that can deal with 
molecules that the human body cannot oth-
erwise break down in a perfect example of 
symbiosis (2). These microorganisms play 
metabolic, trophic and protective roles and 
participate in normal human development 
and homoeostasis, also preventing the over-
growth of potentially harmful bacteria (2). It 
is intuitive to imagine that a continuous in-
terchange occurs between the host organism 
and the microbiota. The perturbation of this 
dialogue results in the so-called dysbiosis 
and there is emerging literature on its role 
in the pathogenesis of systemic autoimmune 
disease such as type 1 diabetes, celiac dis-
ease, ankylosing spondylitis and rheumatoid 
arthritis (3-6). This review aims to summa-
rise current data on the role of the gastroin-
testinal involvement in the pathogenesis of 
systemic rheumatic disease, focusing on GI 
histopathological changes.
n	 HISTOLOGICAL 
CHANGES IN THE GUT 
OF SPONDYLOARTHRITIS 
PATIENTS
Spondyloarthropathy (SpA) refers to a 
group of articular inflammatory diseases 
that share common genetic, clinical and 
radiological features in addition to their 
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association with the human leukocyte an-
tigen (HLA)-B27 antigen (7-9). The hall-
mark of the disease is the inflammation 
of the bone marrow located in the spine 
and in extra-spinal sites (9). Although the 
pathogenesis of SpA is still elusive, acti-
vation of innate and adaptive immune re-
sponses has been reported in SpA patients 
(7). The prototype of these diseases is an-
kylosing spondylitis (AS). Other diseases 
include reactive arthritis, psoriatic arthritis 
(PsA) and arthritis associated with inflam-
matory bowel disease (10). The role of the 
gastrointestinal tract in the pathogenesis 
of SpA is strongly suggested by a grow-
ing body of evidence. In particular, a sub-
clinical gut inflammation documented by 
ileocolonoscopy (macroscopical or micro-
scopical lesions) is present in up to 60% of 
patients with SpA, asymptomatic for signs 
and symptoms of intestinal inflammation 
(11-14). SpA-associated gut inflammation 
seems to be not only an epiphenomenon of 
the ongoing systemic inflammatory pro-
cess. It has in fact been demonstrated that 
gut inflammation is an important prognos-
tic factor in SpA, being associated with 
more extensive bone marrow edema of the 
sacroiliac joints and a higher risk of pro-
gression to ankylosing spondylitis (AS) 
and of developing CD (13). 
n	 ANKYLOSING SPONDYLITIS
Historically, the histological appearance of 
intestinal lesions in ankylosing spondylitis 
(AS) patients has been referred to as the 
acute or chronic type of inflammation (12). 
The acute type resembles a self-limiting 
bacterial enterocolitis characterized by 
the preservation of mucosal architecture, 
infiltration of ileal villi and crypt epithe-
lium with polymorphonuclear cells and an 
increased number of inflammatory cells in 
the lamina propria (12, 15). The chronic 
type of inflammation resembles chronic 
ileocolitis and is characterized by the dis-
tortion of crypts, atrophy of the villous 
surface of the colonic mucosa, blunting 
and fusion of villi, increased mixed lamina 
propria cellularity and basal lymphoid ag-
gregates in the propria inflammation of-
ten resembling the ileocolitis observed in 
Crohn’s disease (12, 15). In some cases of 
chronic lesions, aphthoid ulcers, branch-
ing of the crypts, pseudo-pyloric metapla-
sia and Crohn’s disease-like granulomas 
are present. It is unclear whether the acute 
and chronic forms are a continuation of 
the same histopathological spectrum and 
whether there is a transition from one form 
to another, and in which percentage of pa-
tients one can observe a histological heal-
ing. What we do know is that up to 10% 
of patients with chronic gut inflammation 
will develop over the time a clinically overt 
CD (14). More recently, however, several 
studies from our group have demonstrat-
ed the occurrence of specific histological 
changes in AS gut independently of the 
degree of intestinal inflammation. Goblet 
cells hyperplasia and increased mucin pro-
duction has in fact been proved in AS and 
correlated with the increased expression of 
IL-22, a protective cytokine (16). Paneth 
cells (PC), along with goblet cells, entero-
cytes, and enteroendocrine cells, represent 
the principal cell types of the epithelium of 
the small intestine (17). They are localized 
below the intestinal stem cells in the in-
testinal glands (crypts of Lieberkühn) and 
are characterized by the presence of large 
eosinophilic refractile granules in their 
cytoplasm. PC secrete antimicrobial pep-
tides in response to bacterial antigens into 
the lumen of the intestinal gland, thereby 
contributing to maintenance of the gastro-
intestinal barrier (17). Activation of PC, 
characterized by the increased production 
of antimicrobial peptides, has been dem-
onstrated in AS gut (17). In addition, PC 
represents the most important site where 
the production of IL-23, a key cytokine 
involved in the regulation of innate and 
adaptive immune responses, takes place in 
AS (15). Other histological alterations are 
represented by the detachment of epithe-
lial cells from the basal membrane and the 
occurrence of vasculitic lesions, mainly 
represented by intense hemorrhagic ex-
travasation in the context of the lamina 
propria. Interestingly, similar tissue dam-
ages have been described as a consequence 
of the response of epithelial cells to bacte-
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rial toxins (1). In a recent paper, the pres-
ence of these histological alterations has 
been correlated in AS with the presence 
of adherent and invading bacteria (3). The 
presence of intestinal dysbiosis, confirmed 
by other studies, might be responsible for 
the alteration of the intestinal epithelial 
and vascular barrier observed in AS gut 
(18). In healthy individuals, the intestinal 
microbiota cannot access the liver, spleen, 
or other peripheral tissues. Some patho-
genic bacteria can reach these sites, how-
ever, and can induce a systemic immune 
response. Such compartmentalization is 
guaranteed by the presence of an epithe-
lial gut barrier (consisting of a single-cell 
layer) and of a gut-vascular barrier (GVB) 
that controls the translocation of antigens 
into the blood stream and prohibits entry 
of the microbiota (1, 19). Disruption of the 
intestinal gut barrier and GVB occurs in 
AS patients and is linked to the presence 
of bacteria that induce the production of 
zonulin (20). Zonulin (haptoglobin 2 pre-
cursor) is a protein that modulates the per-
meability of tight junctions between cells 
of the wall of the digestive tract. In AS gut, 
Zonulin expression is up-regulated and 
modulated by isolated intestinal bacteria 
(18). The functional relevance of zonulin 
up-regulation seems to be linked to the 
disruption of the epithelial and vascular 
intestinal barrier (18). The relative contri-
bution of the genetic factors involved in 
SpA pathogenesis in influencing these his-
tological changes cannot be excluded and 
requires further study. Given the absence 
of reliable markers, the diagnosis of intes-
tinal inflammation in SpA is essentially 
made by means of endoscopy. Recently, 
however, elevated serum calprotectin and 
c-reactive protein (CRP) have been dem-
onstrated to be independently associated 
with microscopic bowel inflammation in 
AS (21). In the presence of intestinal in-
flammation, fecal calprotectin is elevated, 
indicating the migration of neutrophils 
to the inflamed intestinal mucosa. In this 
study, the Authors suggest a screening ap-
proach where initially serum calprotectin 
and CRP are assessed and, if necessary, 
fecal calprotectin. The model using this 
scenario provided an area under the ROC 
curve of 74.4% for detection of bowel in-
flammation (21). 
n	 PSORIATIC ARTHRITIS
Gut inflammation has been demonstrated 
to occur also in patients affected by pso-
riatic arthritis (PsA) (22). Schatteman et 
al demonstrated that gut inflammation is 
only present in PsA subgroups that belong 
to the spondyloarthropathy concept and is 
associated with HLA-B27 and Bw62 (22). 
In their study, the prevalence of gut inflam-
mation in psoriatic SpA was significantly 
lower than in non-psoriatic SpA. In a sub-
sequent study, Mielants and co-workers 
(12) prospectively evaluated the clinical 
evolution of different forms of SpA in 
relation to the type of gut histology in il-
eocolonoscopic biopsy specimens. Gut in-
flammation, mainly subclinical, could be 
demonstrated in 68% of patients with SpA 
(10) and patients with non-AS-SpA and 
with inflammatory gut lesions have greater 
risk of developing AS. On the other hand, 
the presence of chronic gut inflammation, 
the persistence of high inflammatory se-
rum variables and HLA-B27 negativity in 
the presence of sacroiliitis or AS are risk 
factors for developing inflammatory bowel 
diseases (23). Scarpa et al evaluated co-
lonic mucosa of patients with both active 
psoriasis and psoriatic arthritis (PsA) with-
out bowel symptoms (24). In their study, 
40% of the patients enrolled had macro-
scopically normal colonic mucosa. In the 
remaining 60% reddening was frequently 
recorded, while edema and granular chang-
es appeared less commonly. Friability was 
markedly rare and bleeding and ulcera-
tions were absent. All the patients showed 
microscopic changes mainly characterized 
by the increase in lamina propria cellular-
ity (consisting of plasma cells and lym-
phocytes) and lymphoid aggregates were 
found in all cases (24). Active inflamma-
tion, evident as neutrophilic polymorpho-
nuclear cell infiltration also frequently oc-
curred. Glandular atrophy, mucosal surface 
changes and crypt abnormalities were rare-
ly observed. The occurrence of subclinical 
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gut inflammation in PsA has been recently 
confirmed by our group in a recent study 
(25). In this study, PsA subclinical gut in-
flammation was characterized by a clear 
Th17 and Th22, but not Th1, polarized im-
mune response. In contrast with AS and 
CD, a strong and significant up-regulation 
of IL-9 was observed in PsA gut, especially 
among infiltrating mononuclear cells, high 
endothelial venules, and PC (25). IL-9-pos-
itive mononuclear cells were demonstrated 
to be in large part Th9 cells and IL-9 over-
expression was accompanied by significant 
PC hyperplasia. PC strongly overexpressed 
IL-9R, and stimulation of epithelial cells, 
isolated from PsA patients, with IL-9 re-
sulted in overexpression of α-defensin 5 
and IL-23p19, indicating a role for IL-9 in 
modulating PC function (25). Similarly to 
AS, subclinical gut inflammation in PsA 
patients appears to be accompanied by 
the presence of a specific microbiological 
signature (26). In this regard, Scher et al 
recently demonstrated that the gut micro-
biota observed in patients with PsA and 
patients with skin psoriasis is less diverse 
when compared to that in healthy con-
trols (26). This could be attributed to the 
reduced presence of several taxa. Samples 
from both patient groups showed a rela-
tive decrease in abundance of Coprococcus 
species, while samples from PsA patients 
were also characterized by a significant re-
duction in Akkermansia, Ruminococcus, 
and Pseudobutyrivibrio. Supernatants of 
fecal samples from PsA patients revealed 
an increase in sIgA levels and decrease 
in RANKL levels. Analysis of fatty acids 
revealed low fecal quantities of hexanoate 
and heptanoate both in patients with PsA 
and patients with psoriasis.
n	 JUVENILE CHRONIC 
ARTHRITIS
Several studies have demonstrated the oc-
currence of histological changes in patients 
with juvenile chronic arthritis. Mielants et 
al. (27) performed ileocolonoscopy with 
biopsy of the ileum, ileocecal valve and 
cecum  on 32 patients presenting juvenile 
chronic arthritis (JIA) with  pauci-articular 
onset. Twenty-two patients (68%) were 
HLA-B27 positive and 8 patients (25%) 
carried the HLA-Bw62 antigen. In this 
study, in the majority of patients presenting 
JIA with pauci-articular onset, gut inflam-
mation was found on ileum biopsy. In par-
ticular, fourteen patients had macroscopic 
lesions of the ileum and ileocecal valve 
although only 8 of these had a history of 
intestinal complaints (27). Twenty-six pa-
tients (81%) presented histological signs 
of gut inflammation mostly classified as 
active chronic or Crohn-like lesions. Only 
7 patients had acute or bacterial enteritis-
like lesions. All the HLA-Bw62 positive 
patients had histological evidence of gut 
inflammation with chronic or Crohn-like 
lesions. The presence of chronic gut in-
flammation on gut biopsy seems to be a 
predictive factor in juveniles for evolution 
to AS (28). In a subsequent study, Pichler 
et al evaluated the histopathological fea-
tures of gastrointestinal mucosal biopsies 
in children with juvenile idiopathic arthritis 
(29). Of the 33 children enrolled, 28 (85%) 
had gut mucosal inflammation, mostly af-
fecting the colon (80%). Active inflam-
mation of the gut was found in 5 out of 28 
(17%) children, while 15 out of 28 (53%) 
children showed mild nonspecific inflam-
mation. Eight patients (27%) had predomi-
nantly an eosinophilic infiltrate (29). The 
Authors demonstrated a negative associa-
tion with the use of immunosuppressors 
and the presence of eosinophil inflamma-
tion (29). Gut microflora and dysbiosis 
have been also linked to the pathogenesis 
of juvenile idiopathic arthritis. Di Paola et 
al in a recent study compared the faecal mi-
crobiota composition of JIA patients with 
healthy subjects (HS), evaluating differ-
ences in microbial profiles between sub-
categories of JIA, such as enthesitis-related 
arthritis (JIA-ERA), in which inflammation 
of entheses occurs, and polyarticular JIA, 
non-enthesitis related arthritis (JIA-nERA) 
(30). Through taxon-level analysis, the au-
thors discovered alteration of faecal micro-
biota components. In particular, abundance 
in Ruminococcaceae in both JIA catego-
ries, reduction in Clostridiaceae and Pepto-
streptococcaceae in JIA-ERA, and increase 
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in Veillonellaceae in JIA-nERA were dem-
onstrated respectively, compared with con-
trols (30). Among the more relevant genera, 
the authors found an increase in Clostrid-
ium cluster XIVb, involved in colitis and 
arthritis, in JIA-ERA patients compared 
with controls, and a trend of decrease in 
Faecalibacterium, known for anti-inflam-
matory properties, in JIA-nERA compared 
with JIA-ERA and controls. Differential 
abundant taxa identified JIA patients for 
the HLA-B27 allele, including Bilophila, 
Clostridium cluster XIVb, Oscillibacter, 
and Parvimonas. Prediction analysis of 
metabolic functions showed that JIA-ERA 
metagenome was differentially enriched in 
bacterial functions related to cell motility 
and chemotaxis, suggesting selection of 
potential virulence traits (30). Finally, the 
authors demonstrated differential microbial 
profiles and intra-group variability among 
active disease and remission, suggesting in-
stability of the microbial ecosystem in au-
toimmune diseases (30). Gut microbiome 
in children with enthesitis-related arthritis 
in a developing country and the effect of 
probiotic administration have been recently 
studied (31). In this study, patients showed 
abundance of Bacteroidaceae and Entero-
bacteriaceae families and a decreased rep-
resentation of Prevotellaceae compared to 
controls. Also, genera Bacteroides, Ente-
rococcus and Klebsiella were over-rep-
resented and genus Prevotella was under-
represented in ERA patients. Interestingly, 
Probiotic therapy led to a non-significant 
increase in Prevotellaceae (31). 
n	 HISTOLOGIC CHANGES  
IN THE GUT OF BEHCET’S 
DISEASE PATIENTS
Behçet’s disease is a rare, chronic, autoim-
mune, auto-inflammatory disorder of un-
known origin that results in inflammation 
of the blood vessels and tissues. Behçet’s 
disease involves the gastrointestinal tract in 
10-15% of cases with localized lesions in 
the ileocecal region (32). The clinical pic-
ture is heterogeneous with various clusters 
of disease expression. Asakura et al. (33) 
demonstrated the presence of marked lym-
phangiectasia in the lamina propria of bi-
opsy specimens of jejunal mucosa and the 
presence of ulcers and healed ulcers of the 
large intestine. Electron microscopic stud-
ies showed that there were thousands of 
precipitated lymph protein bodies in the ex-
tracellular spaces of the lamina propria. A 
recent study from our group demonstrated 
the occurrence of a subclinical gut inflam-
mation in patients with Behçet’s disease 
accompanied by a predominant Th1, but 
not a Th17, response (34). Gut microbiota 
compositional alteration might be associ-
ated with immune dysfunction in patients 
with Behcet’s disease. In particular, Shimi-
zu et al. demonstrated that the genera Bifi-
dobacterium and Eggerthella are increased 
significantly and the genera Megamonas 
and Prevotella decreased significantly in 
Behçet’s disease patients compared with 
normal individuals (35). A linear discri-
minant analysis (LDA) of bacterial taxa 
showed that the phylum Actinobacteria, 
including Bifidobacterium, and the family 
Lactobacillaceae exhibited larger positive 
effect sizes than other bacteria in patients 
with Behçet’s disease. Consolandi et al. 
recently found that Behçet’s patients were 
significantly depleted in the genera Rose-
buria and Subdoligranulum and showed 
a significant decrease of butyrate produc-
tion. Since that butyrate is able to promote 
differentiation of T-regulatory cells, these 
results might consequently indicate that a 
defect of butyrate production might lead 
to both reduced T-reg responses and acti-
vation of immunopathological T-effector 
responses (36).
n	 HISTOLOGICAL CHANGES  
IN THE GUT OF RHEUMATOID 
ARTHRITIS PATIENTS
The prevalence of morphologic bowel le-
sions in patients with rheumatoid arthritis 
(RA) was studied by Porzio et al. (37) in 
1997. During the endoscopic examination, 
gut inflammation was observed in 11% of 
RA patients. At the histological examina-
tion 15% of RA patients showed ultra-
structural alterations and at the electron 
microscopic 50% displayed significant al-
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terations (37). According to the presence of 
subclinical gut inflammation, an increased 
intestinal permeability was found in RA 
patients, even though essentially linked to 
the intake of anti-inflammatory drugs (38). 
Nissinen et al. studied whether inflamma-
tion in the RA gut is associated with im-
mune system activation (39). In particular 
these Authors examined the expression of 
chemokine receptors and cytokine-specific 
mRNA in intestinal biopsy samples from 
patients with RA (39). The Authors dem-
onstrated that the mRNA expression of 
CCR4, CCR5 and IL10, but not of IL2, 
IFNgamma, TNFalpha, or TGFbeta, in 
intestinal biopsy samples was increased 
in patients with RA in comparison with 
control subjects (39). Specific alterations 
in the gut and oral microbiomes in indi-
viduals with RA has been recently demon-
strated, suggesting potential ways of using 
microbiome composition for prognosis and 
diagnosis (40). In particular, alterations in 
the gut, dental or saliva microbiome distin-
guished individuals with RA from healthy 
controls, were correlated with clinical 
measures and could be used to stratify in-
dividuals on the basis of their response to 
therapy. In particular, Haemophilus spp. 
were depleted in individuals with RA gut 
and negatively correlated with levels of se-
rum autoantibodies, whereas Lactobacillus 
salivarius was over-represented in the gut 
of individuals with RA and was present in 
increased amounts in cases of very active 
RA (40). Functional studies revealed that 
the redox environment, transport and me-
tabolism of iron, sulphur, zinc and arginine 
were altered in the microbiota of individu-
als with RA. Supporting the role of RA 
intestinal dysbiosis in the pathogenesis of 
the disease is the recent demonstration that 
probiotic supplementation improves in-
flammatory status in patients with RA (41).
n	 HISTOLOGICAL CHANGES 
IN THE GUT OF SYSTEMIC 
LUPUS ERYTHEMATOSUS 
PATIENTS
Systemic lupus erythematosus (SLE) is an 
autoimmune inflammatory disease char-
acterized by the presence of a wide range 
of autoantibodies potentially affecting 
every system and organ (42). Although 
gastrointestinal manifestations, sometimes 
life-threatening, are common in SLE pa-
tients, it is thought that most of them are 
iatrogenic or due to infection. However, 
since SLE gastrointestinal manifestations 
are indistinct and may not have abdomi-
nal symptoms, it is possible that their in-
cidence might be underestimated. Takeno 
et al. demonstrated that 60%-70% of SLE 
patients had autoptic evidence of peritoni-
tis, whereas only around 10% of them were 
recognized clinically (43).
The most frequent gastrointestinal mani-
festation in SLE patients is represented by 
lupus mesenteric vasculitis (LMV), which 
is one of the main causes of acute abdomi-
nal pain in SLE patients. It can be classified 
as an acute ischemic enteritis that involves 
mainly small intestine and chronic multi-
ple ulcers and occurs mainly in the colon. 
The proposed pathogenic mechanisms of 
LMV are the occurrence of inflammatory 
vasculitis secondary to immune complex 
deposition and thrombosis of the intestinal 
vessels secondary to circulating antiphos-
pholipid antibodies (43). 
Protein-losing gastroenteropathy (PLGE), 
characterized by profound edema and se-
vere hypoalbuminemia secondary to exces-
sive loss of serum protein from the gastro-
intestinal tract, is sometimes observed in 
SLE patients (44). In many patients, the 
typical features of PLGE develop before 
the diagnosis of SLE. In Zheng’s study, 
53.3% of patients had PLGE as the initial 
presentation of SLE, but PLGE could also 
occur 17 years after the establishment of 
SLE (44). 
The pathogenic mechanisms of SLE-as-
sociated PLGE are still unclear. Different 
histological alterations such as mucosal 
ulceration, non-necrotizing mesenteric or 
intestinal vessel vasculitis, increase in cap-
illary permeability caused by complement 
activation, pro-inflammatory cytokines, 
and intestinal lymphangiectasia have been 
described in SLE-associated PLGE (44). 
Less frequently, SLE patients might de-
velop intestinal pseudo-obstruction (IPO), 
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which is the result of the alteration of the 
visceral smooth muscle, the enteric nerve 
and of the visceral automatic nervous sys-
tem. Intestinal leiomyocyte damage due 
to vasculitis leading to chronic ischemia 
of the bowel smooth muscle has been pro-
posed as the main pathogenic alterations 
responsible for SLE-associated IPO (45, 
46). Other rare gastrointestinal manifesta-
tions in SLE patients are represented by 
the co-existence of celiac disease (47), eo-
sinophilic gastroenteritis and inflammatory 
bowel disease (48, 49).
n	 HISTOLOGICAL CHANGES 
IN THE GUT OF SYSTEMIC 
SCLEROSIS PATIENTS
Gastrointestinal involvement is present in 
nearly all patients with SSc and often rep-
resents the first non–Raynaud phenomenon 
symptom (50). Gastrointestinal manifesta-
tions of mild or severe entity may occur in 
patients with both limited or diffuse dis-
ease. The entire gastrointestinal tract may 
be involved as the consequence of smooth 
muscle atrophy and fibrosis within the gas-
trointestinal mucosa and of vascular inti-
mal proliferation (50). The most frequent 
histological alterations are represented by 
mucosal telangiectasias, pseudo-obstruc-
tion and large-intestinal mucosal muscular 
atrophy (51).
n	 CONCLUSIONS
Intestinal histological alterations are com-
mon in rheumatic diseases. In many rheu-
matic diseases intestinal inflammation 
appears to be linked to dysbiosis and pos-
sibly represents the common denominator 
in the pathogenesis of different rheumatic 
diseases. The exact contribution of genetic 
factors in the development of intestinal in-
flammation in rheumatic diseases needs to 
be clarified. Further studies are strongly 
required to clarify the exact contribution 
of the gut in the pathogenesis of the indi-
vidual rheumatic diseases.
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